People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| PierianDx, Inc. | — | Biotechnology | Series B | $41.9M | $443.4M | 2018 |
| Damen 4 Management, LLC | — | Other Health Care | Series A | $7.0M | $141.3M | 2016 |
| Knaq, Inc. | — | Other Technology | Series A | $4.8M | $15.3M | 2023 |
Brian Carey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Carey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles Boorady | 1 | 8 |
| Kerry Propper | 1 | 6 |
| Mark McDonough | 1 | 5 |
| Michael Sanderson | 1 | 4 |
| Reid Robison | 1 | 4 |
| John Neamonitis | 1 | 3 |
| James Starr | 1 | 2 |
| Peter Jobse | 1 | 1 |
| Barnard Buscemi | 1 | 1 |
| Rakesh Nagarajan | 1 | 1 |
| Joseph Boorady | 1 | 1 |
| Frederick Hessler | 1 | 1 |
| Bryan Carey | 1 | 1 |
| Chris Callahan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.